And again it is a “targeted” medicine! In previous attempt as an active part was used doxorubicin. In the present approach – lead-212.
Areva Med LLC (Bethesda, Md.) partnered with Roche (SIX:ROG; OTCQX:RHHBY) to develop an alpha radioimmunotherapy platform to treat cancer. Roche's Pharma Research & Early Development organization (pRED) will combine the pharma's antibodies with Areva's radionuclide, Lead-212. Roche will have exclusive commercialization rights to the radioimmunotherapy after clinical development. Details were not disclosed. Lead-212 is an isotope that is part of the thorium-228 decay chain. Areva Med is a subsidiary of Areva (Euronext:AREVA).
Well, the same targeted approach. Will this particular attempt break the negative expectations regarding “targeted” drugs?
No comments:
Post a Comment